Lv4
550 积分 2021-06-15 加入
CD33 directed bispecific antibodies in acute myeloid leukemia
1天前
待确认
Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients
3天前
已完结
The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment
3天前
已完结
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
13天前
已完结
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
16天前
已完结
Oncology Combination Drug Development Strategies for Project Optimus
21天前
已完结
Physiological parameters in laboratory animals and humans
1个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
1个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
1个月前
已完结
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma
1个月前
已完结
皖公网安备34019202002308
